(Q33367033)

26 July 2017

title

Synthetic and recombinant antithrombin drugs (English)

1 reference

26 July 2017

Kaiser B

1

1 reference

26 July 2017

Callas D

series ordinal

2

1 reference

26 July 2017

Walenga JM

series ordinal

3

1 reference

26 July 2017

Fareed J

series ordinal

4

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 1998

1 reference

Expert Opinion on Investigational Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

7

1 reference

26 July 2017

issue

6

1 reference

26 July 2017

page(s)

963-985

1 reference

A player of many parts: the spotlight falls on thrombin's structure.

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Human protein C and activated protein C Components of the human anticoagulation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

An update on clinical and basic aspects of the protein C anticoagulant pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Endothelial cell function and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Role of endothelium in thrombosis and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Cellular effects of thrombin: pharmacology of the receptor(s) in various cell types and possible development of receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Natural anticoagulant mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

The protein C anticoagulant system: inherited defects as basis for venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

The development of hirudin as an antithrombotic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Triabin, a highly potent exosite inhibitor of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Pharmacologic Aspects of the Development of Selective Synthetic Thrombin Inhibitors as Anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Anticoagulant and Antithrombotic Actions of Recombinant Hirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

21 January 2018

Hirudin and Platelets

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Thrombin and vascular smooth muscle cell proliferation: implications for atherosclerosis and restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

The Role of Thrombin and Thrombin Inhibitors in Coronary Angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Coagulation factor Xa stimulates platelet-derived growth factor release and mitogenesis in cultured vascular smooth muscle cells of rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Specific factor Xa inhibition reduces restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Vascular effects of thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

The thrombin receptor in the nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

alpha-Thrombin increases cytosolic calcium and induces human airway smooth muscle cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Influence of recombinant hirudin and unfractionated heparin on thrombin and factor Xa generation in extrinsic and intrinsic activated systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of alpha-thrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Importance of factor Xa in determining the procoagulant activity of whole-blood clots

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Thrombin receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Thrombin stimulation of renal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

Sustained-release local hirulog therapy decreases early thrombosis but not neointimal thickening after arterial stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.7.6.963

21 January 2018

Identifiers

DOI

10.1517/13543784.7.6.963

1 reference

26 July 2017

1 reference